Bio‑Rad reported modest overall revenue growth driven in part by expansion of its droplet digital PCR (ddPCR) business and stronger consumables pull‑through, the company said on its Q4 call. Management highlighted upgrades across instrument platforms and improved assay sales from a large installed base. Separately, industry commentary explains ddPCR’s technical edge: partitioning samples into droplets and using Poisson statistics enables absolute nucleic acid quantification without standard curves, improving sensitivity for rare-variant detection. Together the commercial results and the technical case position ddPCR as a growing platform in diagnostics and cell & gene therapy development.